Market intelligence for emerging PFTAIRE kinase targets and high-purity reagents for oncology and neurological disease development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CDK15 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | CDK15 Kinase Domain (WT and Gatekeeper Mutant) Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View CDK15 Products |
| Gene Delivery | CDK15 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Endotoxin controlled. |
View CDK15 Products |
| Benchmark Ab | Anti-CDK15 Benchmark Antibody Recombinant positive control for Western blot and ELISA. |
View CDK15 Products |
| Validator | CDK15 siRNA Set For knockdown verification and target validation. |
View CDK15 Products |
| Related Target: CDK16 | CDK16 (PFTAIRE1) Kinase Domain Closest paralog for selectivity counter-screening. |
View CDK16 Products |
| Related Target: CDK14 | CDK14 (PFTAIRE2) Kinase Domain PFTAIRE subfamily member for selectivity screening. |
View CDK14 Products |
| Related Target: CDK4 | CDK4 (Cell Cycle Kinase) Classical CDK for broad selectivity panel. |
View CDK4 Products |
| Related Target: CCNA2 | Cyclin A2 (CCNA2) Cyclin partner for co-crystallization and activity assays. |
View CCNA2 Products |
| Related Target: TRAIL | TRAIL (TNFSF10) Key apoptotic pathway associated with CDK15 resistance mechanisms. |
View TRAIL Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinome Selectivity (Avoiding Off-target Toxicity) | Broad panel of CDK family homolog proteins (CDK15, CDK14, CDK16, CDK4) strictly verified by mass spec and enzymatic activity. |
| PFTAIRE Subfamily Selectivity (vs CDK14/16) | Human CDK15, CDK16, CDK14 Kinase Domains available with >95% purity, Sequence Verified for parallel screening. |
| PROTAC Degradation Assays | High-purity recombinant proteins validated for E3 ligase ternary complex formation (SPR/BLI). |
| ATP-Competitive Inhibitor Screening | High-purity Kinase proteins with confirmed Theoretical MW; suitable for TR-FRET and ADP-Glo biochemical assays. |
| Drug Resistance Mutation Analysis | CDK15 Gatekeeper Mutant proteins available; Sequence Verified for resistance mechanism studies. |
| Target Engagement in Neuronal Models | CDK15 Lentivirus for stable cell line construction; Endotoxin <1EU/ug. Preserves native folding for CETSA/MSA. |
| Lack of Valid Controls | Sequence-verified benchmark antibodies and validated siRNA included for specificity checks. |
Global Clinical Landscape & Future Outlook
The race for CDK therapeutics is intensifying, with major players shifting focus from traditional cell cycle CDKs (like CDK4/6) to novel transcriptional and atypical CDKs such as CDK15 (a member of the PFTAIRE subfamily). As first-generation broad-spectrum kinase inhibitors face toxicity hurdles, the next wave of R&D is targeting highly selective small molecules and PROTAC degraders specifically designed for CDK15 to overcome TRAIL resistance in solid tumors. Emerging evidence also points to CDK15's role in neuronal models, expanding the potential indication scope beyond oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Preclinical biotech | Solid Tumors, Colorectal Cancer | Kinase Activity Assay (Need High-Purity Active Enzymes) |
| PROTAC Degrader | Emerging Startups | Treatment-Resistant Breast Cancer | Ternary Complex Validation (Need Precise Protein Constructs) |
| RNAi / ASO | Academic/Translational | Oncology | Knockdown Validation (Need Reliable Abs & siRNA) |
Live CDK15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: